Cytosorbents Earnings Call Balances Progress And Pressure

Cytosorbents Corp ((CTSO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cytosorbents’ latest earnings call struck a cautiously optimistic tone, as management highlighted modest revenue growth, resilient international demand, and improving adjusted profitability while acknowledging regulatory delays, FX-driven losses, and a tightening cash position. The message to investors was one of disciplined execution under pressure, with a clear path laid out toward eventual cash‑flow breakeven.

Modest Top-Line Growth Amid External Headwinds

Cytosorbents reported Q1 2026 revenue of $8.9 million, a 2% increase year over year that masks a 7% decline on a constant currency basis. Management framed the quarter as resilient given FX volatility and regional disruptions, emphasizing that core demand held up even as reported growth was constrained by macro factors.

International Direct Markets Drive Growth

Outside Germany, direct international sales grew 13% year over year, underscoring strong execution in key hospitals and improving physician awareness of CytoSorb’s benefits. This strength in core international markets is increasingly the engine of growth as the company works through softness in Germany and patchy distributor demand.

Large Installed Base Supports Recurring Revenue Model

Core CytoSorb product sales exceeded $37 million in 2025, with more than 300,000 devices used cumulatively in over 70 countries. Management leaned heavily on this “razor/razor‑blade” model narrative, arguing that the broad installed base provides visibility on recurring consumables revenue and underpins long‑term commercial durability.

Adjusted Profitability Metrics Move in the Right Direction

On an adjusted basis, net loss improved to $3.4 million, or $0.05 per share, from $3.7 million, or $0.06 per share, a year earlier, while adjusted EBITDA loss narrowed to $2.2 million from $2.7 million. These trends reflect tangible benefits from prior cost actions, even as GAAP figures remain weighed down by FX and regulatory spending.

Cost Cuts Reduce Operating Expenses and Cash Burn

Operating expenses fell to $9.2 million from $10.1 million after a roughly 10% headcount reduction executed in late 2025, driving a more than 20% improvement in operating loss to $3.0 million. Cash burn for the quarter improved to about $1.1 million excluding restructuring payments, as management sharpened its focus on spending discipline.

Healthy Margins and Tighter Working Capital Management

Gross margin remained robust at 69%, only modestly below last year’s 71%, despite intentionally slowing production to work down inventory. Stock on hand declined to $4.8 million from $5.3 million, with management stressing that improved working capital efficiency is central to extending its cash runway and supporting future self‑funding.

DrugSorb-ATR: Clinical Validation and Regulatory Path

The STAR‑T randomized trial was published in a leading cardiac surgery journal, showing more than a 50% reduction in severe bleeding when removing ticagrelor, bolstering the clinical case for DrugSorb‑ATR. The device retains two FDA Breakthrough designations, and the company now has clearer direction from regulators, combining real‑world evidence with mechanistic work to support a defined approval path.

Commercial Enablers Support Broader Product Adoption

Management pointed to more than 100 PuriFi pumps placed internationally and a positive reception to the HotSwap device as key enablers of adoption. These platforms are designed to simplify dosing strategies and broaden use across critical care and cardiac surgery, deepening utilization in existing accounts and supporting higher pull‑through of cartridges.

Roadmap to Operating Cash-Flow Breakeven

The company is targeting operating cash‑flow breakeven in the second half of 2026, hinging on continued opex discipline and steady top‑line expansion from its installed base. Executives framed current cost levels and margin structure as sufficient to reach that goal, provided regulatory investments are managed tightly and commercial execution remains solid.

GAAP Net Loss Impacted by Foreign Exchange

Despite adjusted improvements, GAAP net loss widened to $5.1 million, or $0.08 per share, versus $1.5 million, or $0.02 per share, a year ago, primarily due to non‑cash foreign currency transaction losses. Management stressed that these FX effects distort the underlying trajectory but do not reflect deterioration in core operations.

Cash Position Tightens, Raising Liquidity Questions

Total cash, cash equivalents, and restricted cash declined to about $6.4 million at March 31, 2026, from $7.8 million at year‑end, leaving limited near‑term liquidity headroom. While lower cash burn and inventory reductions help, investors will watch closely for how the company funds its extended regulatory timetable and growth initiatives.

FDA De Novo Delay Adds Time and Cost

Cytosorbents disclosed that its appeal of an earlier FDA de novo denial was upheld but came with added requirements for mechanistic non‑clinical data alongside real‑world evidence. As a result, a new de novo submission for DrugSorb‑ATR is now expected in late 2026 or early 2027, implying more time and spending before potential U.S. approval.

Germany Weakness Forces Commercial Restructuring

The company acknowledged that direct sales in Germany declined year over year, though without quantifying the drop, and responded by downsizing and restructuring its German sales organization. Management plans a selective rebuilding of the field force as conditions stabilize, but Germany is likely to be a drag until growth resumes.

Geopolitical Tensions Disrupt Distributor Orders

Distributor sales were flat in the quarter and were dented by geopolitical disruption related to conflict involving Iran, which delayed roughly $0.5 million of expected orders. The impact was felt mainly through the Dubai subsidiary and parts of the EMEA region, illustrating ongoing exposure to regional instability.

Margin Compression from Inventory Actions

Gross margin slipped by about two percentage points to 69%, a change management linked directly to intentionally reduced unit production as it trims inventory levels. They cautioned that margins may remain in the high‑60s to low‑70s range in the near term, a trade‑off they accept to free up working capital and strengthen the balance sheet.

Guidance: Longer Regulatory Timelines but Clear Targets

Looking forward, Cytosorbents reaffirmed its focus on disciplined growth and cost control, reiterating the goal of operating cash‑flow breakeven in the back half of 2026. The company now expects a DrugSorb‑ATR de novo filing in late 2026 or early 2027, is preparing a DOAC pre‑submission, and continues to view its potential U.S. market opportunity in the hundreds of millions of dollars.

Cytosorbents’ call painted a picture of a company balancing near‑term financial and regulatory headwinds with solid underlying demand, strong margins, and growing clinical validation. For investors, the story hinges on whether management can sustain cost discipline and execute through the extended FDA timeline long enough to unlock the sizable DrugSorb‑ATR opportunity.